P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS

P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS

Bibliographic Details
Main Authors:	Lijuan Hu, Wei-LI Zhao, Wen Wu, Xudong Wei, Ruihua MI, Yu Hu, Qiubai LI, Wenjuan He, Juan LI, Yugang Dong, Hehua Wang, Xuhan Zhang, Yu Zhang, Zhongyuan Xu, Hui Liu, Zhen Cai, Jie Sun, Yajing Xu, Zhiping Jiang, Cheng Zhang, Guo Chen, Tiejun Gong, Qinghua Tang, Hongmei Jing, Lan MA, Sujun Gao, Qiqi Liu, Zeyu Zhong, Yongxin Ren, Jian Chen, Songhua Fan, Michael Shi, Weiguo Su, Xiaojun Huang
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000969064.86312.d3

Similar Items

Research progress of IDH1 and IDH2 mutations in gliomas
by: Shan-shan ZHANG, et al.
Published: (2015-11-01)

Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities
by: Matthew Garrett, et al.
Published: (2018-04-01)

Profiling the Effect of Targeting Wild Isocitrate Dehydrogenase 1 (IDH1) on the Cellular Metabolome of Leukemic Cells
by: Mohammed Razeeth Shait Mohammed, et al.
Published: (2022-06-01)

Molecular alterations of isocitrate dehydrogenase 1 and 2 (<it>IDH1 </it>and <it>IDH2</it>) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients
by: Chotirat Sadudee, et al.
Published: (2012-03-01)

Isocitrate protects DJ-1 null dopaminergic cells from oxidative stress through NADP+-dependent isocitrate dehydrogenase (IDH).
by: Jinsung Yang, et al.
Published: (2017-08-01)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
by: Claudio Cerchione, et al.
Published: (2021-03-01)

Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas
by: Felix Neumaier, et al.
Published: (2023-03-01)

Prognostic value of mutations in isocitrate dehydrogenase 1 (IDH1) and reverse telomerase transcriptase (TERT) in Argentine patients` gliomas
by: Pedro Tomás Funes, et al.
Published: (2021-03-01)

IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution
by: Erika F. Rodriguez, et al.
Published: (2020-06-01)

Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma
by: Fengchao Lang, et al.
Published: (2021-09-01)

Exploiting electrode nanoconfinement to investigate the catalytic properties of isocitrate dehydrogenase (IDH1) and a cancer-associated variant
by: Herold, RA, et al.
Published: (2021)

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma.
by: Krell, D, et al.
Published: (2011)

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma.
by: Daniel Krell, et al.
Published: (2011-01-01)

Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report
by: Ali S. Haider, et al.
Published: (2023-04-01)

GENETIC BIOMARKERS OF GLIAL BRAIN TUMORS: IDH1 AND IDH2 MUTATIONS
by: M. Yu. Prokudin, et al.
Published: (2020-09-01)

Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL
by: Mathieu Simonin, et al.
Published: (2021-05-01)

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
by: Mondesir J, et al.
Published: (2016-09-01)

Chronic nickel (II) exposure induces the stemness properties of cancer cells through repressing isocitrate dehydrogenase (IDH1)
by: Lingqiao Wang, et al.
Published: (2021-04-01)

Analysis of Isocitrate dehydrogenase (IDH) mutation in Gliomas---a call for neurosurgeons and pathologists in Pakistan
by: Muntaha Masood, et al.
Published: (2022-05-01)

Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations
by: Emir, U, et al.
Published: (2015)

Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm
by: Ghayas C. Issa, et al.
Published: (2021-06-01)

Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival.
by: Yu Yao, et al.
Published: (2013-01-01)

IDH1: Linking metabolism and epigenetics
by: Raineri, S, et al.
Published: (2018)

IDH1: Linking Metabolism and Epigenetics
by: Silvia Raineri, et al.
Published: (2018-10-01)

Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma
by: Margherita Rimini, et al.
Published: (2022-11-01)

The expression and significance of IDH1 and p53 in osteosarcoma
by: Zhou Min, et al.
Published: (2010-05-01)

Radiosensitization and a Less Aggressive Phenotype of Human Malignant Glioma Cells Expressing Isocitrate Dehydrogenase 1 (IDH1) Mutant Protein: Dissecting the Mechanisms
by: Jacqueline Kessler, et al.
Published: (2019-06-01)

PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations
by: Lea Kristin Röver, et al.
Published: (2018-02-01)

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions
by: Bas J. Wouters
Published: (2021-06-01)

Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma
by: Ayoub Saaid, et al.
Published: (2022-08-01)

Study of mutations in IDH1 and IDH2 genes in a sample of gliomas from Colombian population
by: Orlando Ricaurte, et al.
Published: (2018-05-01)

Access to Isocitrate dehydrogenase (IDH) mutation characterization and prognostication in a Kenyan hospital – A first case
by: Daniel Kanyata, et al.
Published: (2021-09-01)

Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma
by: Daniel Dubinski, et al.
Published: (2021-03-01)

Association of Isocitrate Dehydrogenase (IDH) status with edema to tumor ratio and its correlation with immune infiltration in glioblastoma
by: D. Dubinski, et al.
Published: (2021-01-01)

TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms
by: Nur Soyer, et al.
Published: (2017-05-01)

The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma
by: Anh Huan Vo, et al.
Published: (2022-01-01)

Clonality analysis and IDH1 and IDH2 mutation detection in both components of dedifferentiated chondrosarcoma, implicated its monoclonal origin
by: Tingting Yang, et al.
Published: (2020-06-01)

A noninvasive comparison study between human gliomas with IDH1 and IDH2 mutations by MR spectroscopy
by: Shen, X, et al.
Published: (2019)

Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma
by: James M. Cleary, et al.
Published: (2022-09-01)

IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis.
by: Peng Zou, et al.
Published: (2013-01-01)